PRF Technologies Ltd. (NASDAQ: PRFX) announced results from a preclinical study comparing its drug candidate PRF-110 to an approved pain medication in domestic pigs. The study found PRF-110 provided sustained pain relief comparable to ZYNRELEF over a 72-hour period following surgery.

PRF-110 is an extended-release formulation of ropivacaine designed to be applied directly to surgical wounds before closure. The company is developing the product to provide prolonged local pain relief after surgery through a single administration, with the goal of reducing opioid use for post-surgical pain management.

In the head-to-head study, both PRF-110 and ZYNRELEF produced reductions in pain-related measures in a validated pig incisional pain model. Animals received a single administration of either treatment into the surgical wound bed before closure, with pain assessments conducted at multiple timepoints over 72 hours.

The study found PRF-110's pain relief effect was comparable to ZYNRELEF across the overall assessment period. At later timepoints after surgery, PRF-110 maintained pain relief efficacy comparable to the approved benchmark product.

"PRF-110 demonstrated sustained analgesic activity comparable to an approved benchmark over 72 hours in this head-to-head preclinical study," said Dr. Ehud Geller, Executive Chairman of PRF Technologies. "Importantly, PRF-110 achieved this activity with a ropivacaine-only, NSAID-free formulation."

The company stated PRF-110's safety profile in pigs was consistent with prior preclinical experience, with no unexpected findings at the tested doses. PRF Technologies indicated the findings will inform future development planning for PRF-110, including study design and regulatory strategy.

The information is based on a company press release statement.